We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
CAR T-Cells for T-cell Lymphoma.
- Authors
Hill, LaQuisa C.; Rouce, Rayne H.; Mamonkin, Maksim
- Abstract
Developing CAR T-cells for T-lineage malignancies requires minimizing fratricide of engineered T-cells and mitigating the risk of T-cell aplasia, which may be caused by the off-tumor activity of CAR T-cells. We have developed and optimized for clinical evaluation a CAR targeting pan-T-cell antigen CD5, which is highly expressed in peripheral T-cell lymphoma. Expression of an optimized CD5 CAR produces only transient and limited fratricide as T-cells rapidly internalize and degrade CD5 protein in a CAR-dependent manner. Resulting CD5 CAR T-cells are fratricide-resistant and produce strong anti-tumor activity in mouse xenograft models of human T-cell malignancies.1 Based on this preclinical work, we initiated a Phase I clinical trial at Baylor College of Medicine with autologous CD5 CAR T-cells in patients with refractory or relapsed T-cell malignancies as a bridge to allogeneic HSCT (NCT03081910).
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2021, Vol 21, pS173
- ISSN
2152-2650
- Publication type
Article
- DOI
10.1016/S2152-2650(21)01255-6